ctDNA and MRI Parameters in Head and Neck Cancer
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age19-100
SponsorFranziska Eckert
About this trial
Patients undergoing primary radiochhemotherapy for locally advanced head and neck squamous cell carcinomas are included in this study. In addition to standard of care treatment patients will undergo addiational blood draws and MR imaging studies. Circulating cell free tumor DNA will be analysed in the blood samples. BIological data, imaging data and clinical data (such as patient and tumor characteristics, oncologic outcome, side effects) will be analysed in a biomathematical modelling approach.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Squamous cell carcinoma head and neck
Planned primary platinum based radiochemotherapy
ECOG 0-2
Disqualifiers
Palliative therapy intent
Not MR eligible
Trial design
Design model
Single group
Treatments tested in this trial
Blood draw, MRI
Other interventionBlood draw, MRI
Treatment groups
No treatment groups listed
Trial outcomes
Primary outcomes
1
percentage of patients with 50% decrease in ctDNA
Time frame
7 weeks after start of radiotherapySecondary outcomes
1
Completion of all planned MR imagings and blood tests
Time frame
through study completion, an average of 7 weeks2
Decrease of tumor volume
Time frame
7 weeks after start of radiotherapyLocations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Franziska Eckert
Lead sponsor
Medical University of Vienna
Sponsor institution
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: